Second-Line Rescue Therapy With Levofloxacin After H. pylori Treatment Failure: A Spanish Multicenter Study of 300 Patients
Authors: Gisbert, Javier P.1; Bermejo, Fernando2; Castro-Fernández, Manuel3; Pérez-Aisa, Angeles4; Fernández-Bermejo, Miguel5; Tomas, Albert6; Barrio, José7; Bory, Felipe8; Almela, Pedro9; Sánchez-Pobre, Pilar10; Cosme, Angel11; Ortiz, Vicente12; Niño, Pilar13; Khorrami, Sam14; Benito, Luis-Miguel15; Carneros, Jose-Antonio2; Lamas, Eloisa3; Modolell, Inés6; Franco, Alejandro10; Ortuño, Juan12; Rodrigo, Luis13; García-Durán, Fernando2; O'Callaghan, Elena6; Ponce, Julio12; Valer, María-Paz2; Calvet, Xavier16
Source: The American Journal of Gastroenterology, Volume 103, Number 1, January 2008 , pp. 71-76(6)
Publisher: Wiley-Blackwell
Abstract:
AIM: Quadruple therapy is generally recommended as second-line therapy after Helicobacter pylori (H. pylori) eradication failure. However, this regimen requires the administration of four drugs with a complex scheme, is associated with a relatively high incidence of adverse effects, and bismuth salts are not available worldwide anymore. Our aim was to evaluate the efficacy and tolerability of a triple second-line levofloxacin-based regimen in patients with H. pylori eradication failure. METHODS: Design: Prospective multicenter study. Patients: in whom a first treatment with proton pump inhibitor-clarithromycin-amoxicillin had failed. Intervention: A second eradication regimen with levofloxacin (500 mg b.i.d.), amoxicillin (1 g b.i.d.), and omeprazole (20 mg b.i.d.) was prescribed for 10 days. Outcome: Eradication was confirmed with 13C-urea breath test 4-8 wk after therapy. Compliance with therapy was determined from the interview and the recovery of empty envelopes of medications. Incidence of adverse effects was evaluated by means of a specific questionnaire. RESULTS: Three hundred consecutive patients were included. Mean age was 48 yr, 47% were male, 38% had peptic ulcer, and 62% functional dyspepsia. Almost all (97%) patients took all the medications correctly. Per-protocol and intention-to-treat eradication rates were 81% (95% CI 77-86%) and 77% (73-82%). Adverse effects were reported in 22% of the patients, mainly including nausea (8%), metallic taste (5%), abdominal pain (3%), and myalgias (3%); none of them were severe.CONCLUSION: Ten-day levofloxacin-based rescue therapy constitutes an encouraging second-line strategy, representing an alternative to quadruple therapy in patients with previous proton pump inhibitor-clarithromycin-amoxicillin failure, being simple and safe.(Am J Gastroenterol 2007;102:71-76)Document Type: Research article
DOI: http://dx.doi.org/10.1111/j.1572-0241.2007.01500.x
Affiliations: 1: Hospital de la Princesa, Madrid 2: Hospital de Fuenlabrada, Madrid 3: Hospital de Valme, Sevilla 4: Hospital Costa del Sol, Málaga 5: Hospital San Pedro de Alcántara, Cáceres 6: Hospital General de Cataluña, Barcelona 7: Hospital Río Hortega, Valladolid 8: Hospital del Mar, Barcelona 9: Hospital Clínico, Valencia 10: Hospital 12 de Octubre, Madrid 11: Hospital de Donostia, San Sebastián 12: Hospital La Fe, Valencia 13: Hospital Central de Asturias, Oviedo 14: Hospital Son Llatzer, Palma de Mallorca 15: Hospital Virgen del Toro, Menorca 16: CIBEREHD, Hospital de Sabadell, Barcelona, Spain
Publication date: 2008-01-01
- In this: publication
- By this: publisher
- In this Subject: Gastroenterology
- By this author: Gisbert, Javier P. ; Bermejo, Fernando ; Castro-Fernández, Manuel ; Pérez-Aisa, Angeles ; Fernández-Bermejo, Miguel ; Tomas, Albert ; Barrio, José ; Bory, Felipe ; Almela, Pedro ; Sánchez-Pobre, Pilar ; Cosme, Angel ; Ortiz, Vicente ; Niño, Pilar ; Khorrami, Sam ; Benito, Luis-Miguel ; Carneros, Jose-Antonio ; Lamas, Eloisa ; Modolell, Inés ; Franco, Alejandro ; Ortuño, Juan ; Rodrigo, Luis ; García-Durán, Fernando ; O'Callaghan, Elena ; Ponce, Julio ; Valer, María-Paz ; Calvet, Xavier

Shopping cart
Receive new issue alert
Get Permissions